Abstract
While ovarian carcinomas of the epithelial type are sensitive to a number of chemotherapeutic agents, treatment has not markedly increased the percentage of 5-year survivors having advanced disease at the time of diagnosis. Several groups, including our own, have previously shown that the combination of adriamycin and cyclophosphamide (A-C) induces a high percentage of partial remissions in patients with stages III and IV disease [5, 7]. Unfortunately, remission duration is still relatively short, and it is still too early to determine whether this combination therapy will have an important impact on the prolongation of survival.
Supported by grants from the US Public Health Service (CA 16943, CA 12014, and CA 13612).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Reference
Di Saia, P. J.: Overview of tumor immunology in gynecologic oncology. Cancer 38, 566–580 (1976).
Gall, S. A., Walling, J., et al.: Demonstration of tumor-associated antigens in human gynecologic malignancies. Am. J. Obstet, Gynecol. 115, 387–393 (1973).
Hamburger, A. W., Salmon, S. E. et al.: Direct cloning of human ovarian carcinoma cells in agar. Cancer Res. 38, 3438–3444 (1978).
Khoo, S. K., McKay, E. V.: Immunologic reactivity of female patients with genital cancer: status in preinvasive, locally invasive, and disseminated disease. Am. J. Obstet. Gynecol. 119, 1018–1025 (1974).
Lloyd, R. E., Jones, S. E. et al.: Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial. Cancer Treat. Rep. 60, 77–83 (1976).
Order, S. E., Donahue, V., et al.: Immunotherapy of ovarian carcinoma, an experimental model. Cancer 32, 573–579 (1973).
Parker, L. M., Lokich, J. J. et al.: Adriamycin-cyclophosphamide therapy in ovarian cancer. Proc. AACR and ASCO 16, 263 (1975).
Salmon, S. E., Hamburger, A. W.: Immunoproliferation and cancer: a common macrophage-derived promoter substance. Lancet I, 1289–1290 (1978).
Wolff, J. P., DeOliveira, C. F.: Lymphocytes in patients with ovarian cancer. Obstet. Gynecol. 45, 656–658 (1974).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1979 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Alberts, D.S., Salmon, S.E., Moon, T.E. (1979). Chemoimmunotherapy for Advanced Ovarian Carcinoma With Adriamycin-Cyclophosphamide ± BCG: Early Report of a Southwest Oncology Group Study. In: Bonadonna, G., Mathé, G., Salmon, S.E. (eds) Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II. Recent Results in Cancer Research, vol 68. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81332-0_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-81332-0_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81334-4
Online ISBN: 978-3-642-81332-0
eBook Packages: Springer Book Archive